Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron vs Dapagliflozin in Type 2 Diabetes (ACHIEVE-2)
NCT06192108Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of orforglipron in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Jan 2024; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06192108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06192108.